Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
22.10. | Genflow Biosciences secures EUR4 million for liver disease treatment | 5 | Alliance News | ||
22.10. | Genflow Biosciences PLC: Genflow Secures Non-Dilutive Financial Support | 94 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
22.10. | Genflow Biosciences - Genflow Secures Non-Dilutive Financial Support | 2 | RNS | ||
30.09. | Genflow Biosciences PLC Announces Half-year Report | 185 | ACCESSWIRE | LONDON, UNITED KINGDOM / ACCESSWIRE / September 30, 2024 / Genflow (LSE:GENF) is pleased to announce its half year results for the six-month period ended 30 June 2024.Chairman's StatementIt is with... ► Artikel lesen | |
30.09. | Genflow Biosciences - Half-year Report | 1 | RNS | ||
27.06. | Genflow Biosciences Plc Announces Result of AGM | 244 | ACCESSWIRE | LONDON, UNITED KINGDOM / ACCESSWIRE / June 27, 2024 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing... ► Artikel lesen | |
27.06. | Genflow Biosciences - Result of AGM | 1 | RNS | ||
27.06. | Genflow Biosciences PLC Announces Strengthening of Pre-Clinical Efforts | 209 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
GENFLOW BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
27.06. | Genflow Biosciences - Strengthening of Pre-Clinical Efforts | 1 | RNS | ||
12.06. | EARNINGS AND TRADING: Distil loss widens; Genflow welcomes grant | 1 | Alliance News | ||
12.06. | Genflow Biosciences PLC Announces Receipt of Grant Funding | 135 | ACCESSWIRE | Receipt of Grant Funding LONDON, UK / ACCESSWIRE / June 12, 2024 / THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE... ► Artikel lesen | |
12.06. | Genflow Biosciences - Receipt of Grant Funding | - | RNS | ||
03.06. | Genflow Biosciences PLC Announces Notice of AGM | 180 | ACCESSWIRE | Genflow Biosciences PlcNotice of Annual General Meeting LONDON, UNITED KINGDOM / ACCESSWIRE / June 3, 2024 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging... ► Artikel lesen | |
03.06. | Genflow Biosciences - Notice of AGM | 1 | RNS | ||
30.05. | Genflow Biosciences receives 50% of grant for sarcopenia project | 1 | Alliance News | ||
30.05. | Genflow Biosciences PLC Announces Receipt of Grant Funding | 223 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen | |
30.05. | Genflow Biosciences - Receipt of Grant Funding | 1 | RNS | ||
10.05. | Genflow Biosciences PLC Announces Holding(s) in Company | 266 | ACCESSWIRE | LONDON, UK / ACCESSWIRE / May 10, 2024 / TR-1: Standard form for notification of major holdings1. Issuer DetailsISINGB00BP2C3V08Issuer NameGENFLOW BIOSCIENCES PLCUK or Non-UK IssuerUK2. Reason for NotificationAn... ► Artikel lesen | |
08.05. | XFRA WQ5: WIEDERAUFNAHME/RESUMPTION | 91 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
08.05. | Genflow Biosciences PLC Announces Restoration of Listing | 206 | ACCESSWIRE | THE INFORMATION CONTAINED WITHIN THIS ANNOUNCEMENT IS DEEMED BY THE COMPANY TO CONSTITUTE INSIDE INFORMATION AS STIPULATED UNDER THE MARKET ABUSE REGULATION (EU) NO. 596/2014 AS IT FORMS PART OF UK... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 41,110 | +0,05 % | DAX-Check LIVE: Daimler Truck, Delivery Hero, Heidelberg, Lanxess, Munich Re, Nordex, Qiagen & Co. | Nachdem gestern feststand, dass Donald Trump die US-Wahl für sich entschieden hat, stieg der DAX zunächst um rund 1,5 Prozent an. Doch dann trat schnell Ernüchterung ein. Am Ende gab der DAX 1,13 Prozent... ► Artikel lesen | |
EVOTEC | 8,115 | -8,97 % | US-Wahl und der BioTech-Sektor - ein heißer November steht an! BioNTech, Pfizer, Nyxoah, Bayer oder Evotec? | Mit Spannung geht die Börse nicht nur in die Q3-Berichtsaison, sondern sie blickt auch auf die Wahlergebnisse aus den USA. Denn der knapp führenden Demokratin Kamala Harris wird nachgesagt, dass sie... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 33,000 | -1,55 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights | - Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors... ► Artikel lesen | |
PHATHOM PHARMACEUTICALS | 9,530 | 0,00 % | Phathom Pharmaceuticals, Inc. - 10-Q, Quarterly Report | ||
BIONTECH | 101,60 | -0,39 % | DEUTSCHE BANK RESEARCH stuft Biontech auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Biontech nach einer Telefonkonferenz zu den Quartalszahlen auf "Buy" mit einem Kursziel von 150 US-Dollar belassen. Die Aktie... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,75 | 0,00 % | Longboard Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Updates | LA JOLLA, Calif.--(BUSINESS WIRE)--Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 7,570 | 0,00 % | Recursion releases OpenPhenom-S/16 for microscopy data | ||
TAYSHA GENE THERAPIES | 2,380 | 0,00 % | Taysha Gene Therapies Inc Aktie: Unternehmensstrategien und deren Umsetzung | Die Aktie von Taysha Gene Therapies Inc, einem Unternehmen für Gentherapien, verzeichnete am 9. November 2024 einen bemerkenswerten Kursanstieg von 5,63% auf 1,50 USD. Dieser Zuwachs ist besonders erwähnenswert... ► Artikel lesen | |
HARMONY BIOSCIENCES | 35,070 | 0,00 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
BB BIOTECH | 41,700 | -2,00 % | BB Biotech Aktie: Weiterhin auf Erfolgskurs! | Die BB Biotech-Aktie verzeichnete am 1. November 2024 einen beachtlichen Kurssprung auf 39,85 EUR und überschritt damit die bedeutsame 50-Tage-Linie. Diese positive Entwicklung deutet auf ein gesteigertes... ► Artikel lesen | |
MODERNA | 40,980 | +0,10 % | Ihre wichtigsten Termine: Heute: Pinterest, Moderna, Airbnb, Daimler Truck& Delivery Hero legen Zahlen vor | © Foto: Bodo Schackow/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:45... ► Artikel lesen | |
STRYKER | 364,60 | +0,03 % | Stryker Co. (NYSE:SYK) CEO Sells $21,131,303.10 in Stock | ||
ADMA BIOLOGICS | 21,770 | -3,16 % | ADMA Biologics-Aktie erreicht Allzeithoch von 21,25 US-Dollar | ||
KEROS THERAPEUTICS | 64,83 | -4,87 % | Keros Therapeutics, Inc.: Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results | LEXINGTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
JANUX THERAPEUTICS | 52,87 | 0,00 % | Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights | SAN DIEGO--(BUSINESS WIRE)--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary... ► Artikel lesen |